CRM vs DHR: Which Is the Better Buy?

Side-by-side comparison of Salesforce, Inc. and Danaher Corporation — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-05-04.
Salesforce, Inc. · Technology
$182.14
+200.4% upside to fair value
Grade B High Quality
VS
Danaher Corporation · Healthcare
$174.04
+13.2% upside to fair value
Grade B
QuantHub Verdict
CRM has more upside to fair value (+200.4%). CRM trades at a lower forward P/E (22.8x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric CRM DHR
Current Price $182.14 $174.04
Fair Value Estimate $547.17 $197.01
Upside to Fair Value +200.4% +13.2%
Market Cap $173.0B $123.2B
Forward P/E 22.8x 33.4x
EV / EBITDA 14.4x 20.3x
Price / Sales 4.2x 5.0x
Price / FCF 12.0x 23.3x
Revenue Growth YoY +12.1% +3.7%
Gross Margin 77.7% 60.7%
Operating Margin 21.5% 21.0%
Return on Equity 12.4% 7.1%
Dividend Yield 0% 0%
FCF Yield 8.33% 4.3%
Analyst Consensus Buy Strong Buy
Investment Thesis
CRM — Salesforce, Inc.
Salesforce, Inc. is a leading enterprise software company specializing in cloud-based customer relationship management and enterprise applications. The company benefits from a durable competitive moat anchored by pioneering SaaS delivery, a large and growing customer base, and a diversified revenue mix with Service Cloud as the largest segment generating $9.05 billion in FY2025. Salesforce exhibi…
DHR — Danaher Corporation
Danaher Corporation is a diversified healthcare company focused on medical diagnostics, life sciences, and biotechnology, generating approximately $24 billion in revenue with a strong recurring revenue base of over 81%. The company benefits from a high gross margin of 60.7% and solid operating margin of 21%, supported by a seasoned management team with a proven capital allocation track record inc…
Accumulation Zones
Metric CRM DHR
Zone Low $410.38 $147.76
Zone High $465.09 $167.46
In Buy Zone? Yes No
← CRM Research    DHR Research →    All Research